Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations

NCT02738931 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Infection, Human Immunodeficiency Virus

Interventions

DRUG: Dolutegravir 50 mg tablet
DRUG: Lamivudine 300 mg tablet
DRUG: Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA)
DRUG: Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AB)

Sponsor

ViiV Healthcare

Collaborators

[object Object]